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Abstract Simultaneous quantiﬁcation of Lamivudine and Zidovudine in tablets by HPTLC
method was developed and validated. The chromatograms were developed using a mobile phase of
toluene:ethyl acetate:methanol (4:4:2, v/v/v) on pre-coated plate of silica gel GF aluminum TLC
plate and quantiﬁed by densitometric absorbance mode at 276 nm. The Rf values were 0.4170.03
and 0.6070.04 for Lamivudine and Zidovudine, respectively. The linearity of the method was
found to be within the concentration range of 50250 ng/spot for Lamivudine and for Zidovudine,
it was 100500 ng/spot. The lower limits of detection and quantiﬁcation were 2.23 ng/spot and
7.90 ng/spot for Lamivudine and 2.90 ng/spot and 8.85 ng/spot for Zidovudine. The method was
also validated for precision, speciﬁcity and recovery. This developed method was used to analyze
ﬁxed-dose tablets (Duovir, Cipla Ltd) samples of Lamivudine and Zidovudine.
& 2011 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.
1. Introduction
Lamivudine (4-amino-1-[(2R,5S)-2-(hydroxymethyl)-1,3-oxathio-
lan-5-yl]-1,2dihydro pyrimidine-2-one) (Fig. 1A) and Zidovudine
(1-[(2R,4S,5S)-4-azido-5-(hydroxymethyl) oxolan-2-yl]-5-methyl-
1,2,3,4-tetrahydropyrimidine-2,4-dione) (Fig. 1B) were anti-HIV
drugs (reverse transcriptase inhibitors). Lamivudine and Zidovu-
dine have been reported to be quantiﬁed individually or in
combination with other drugs [1–3]. The literature survey reveals
that there are analytical methods available for determination of
Lamivudine and Zidovudine from biological matrices, bulk drug
and dosage forms, and for determination of Lamivudine
and Zidovudine with combination of other antiviral drugs by
RP-HPLC/MS [4–7].
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Figure 1 (A) Lamivudine and (B) Zidovudine.
Simultaneous analysis of Lamivudine and Zidovudine in tablets by HPTLC method 153Habte et al. [8] had reported HPTLC method for the
analysis of Lamivudine and Zidovudine using the solvent
system of toluene/chloroform/methanol (1:6:3, v/v/v) with the
lower limit of detection and quantiﬁcation of 3.06 ng/spot and
9.28 ng/spot for Lamivudine and 3.34 ng/spot and 10.13 ng/
spot for Zidovudine. In this study, we report the HPTLC
method for the analysis of Lamivudine and Zidovudine using
a solvent system of toluene:ethyl acetate:methanol (4:4:2, v/v/v),
the lower limits of detection and quantiﬁcation are 2.23 ng/
spot and 7.90 ng/spot for Lamivudine and 2.98 ng/spot and
8.85 ng/spot for Zidovudine.2. Experimental
2.1. Chemicals and reagents
Pure Lamivudine powder and Zidovudine powder were kind
gifts from Micro Labs, Bangalore, India. Commercial tablets
(Duovir, Cipla Ltd) containing Lamivudine (150 mg) and
Zidovudine (300 mg) were used for the study. Toluene, ethyl
acetate and methanol used were of analytical grade (E. Merck,
Mumbai, India). All the other chemicals used were also of
analytical grade (E. Merck, India).
2.2. Instrumentation and conditions
HPTLC plates pre-coated with silica gel GF aluminum TLC
plate, (10 cm 10 cm) were from Merck. Densitometry was
carried out with a CAMAG TLC Scanner 3, ﬁtted with a win-
CATS 1.4.0 planar chromatography manager software. Samples
were applied to the HPTLC plates using the spray-on technique
of CAMAG LINOMAT V under nitrogen gas ﬂow, and
developed in a CAMAG 10 cm 10 cm twin trough chambers.
2.3. Standard preparation
Lamivudine and Zidovudine (10 mg each) were accurately
weighed and transferred into 10 mL volumetric ﬂasks, and
dissolved in 10 mL of methanol. Both solutions were further
diluted with methanol to get the ﬁnal concentration of 2 mg/mL.
The stock solutions were further diluted with methanol to obtain a
working standard solution with ﬁnal concentrations of 50, 100,
150, 200 and 250 ng/mL for Lamivudine and 100, 200, 300, 400
and 500 ng/mL for Zidovudine respectively, which were used for
calibration purposes.
2.4. Preparation of sample solution
For analysis of tablet dosage form, twenty tablets, each
containing 150 mg of Lamivudine and 300 mg Zidovudine,
were weighed and their average weight was calculated. The
tablets were ﬁnely powdered and powder equivalent to 10 mg
Lamivudine and Zidovudine was accurately weighed and
dissolved in 10 mL of methanol. The solution was sonicatedfor 30 min, ﬁltered through the Whattman No. 41 ﬁlter paper
and the residue was washed with methanol. The volume of the
ﬁltrate was adjusted to 10 mL with the same solvent. This
solution was further diluted with methanol to get the same
concentration as that of the ﬁnal standard solution.
2.5. Chromatographic conditions
Lamivudine and Zidovudine reference standard solutions were
prepared using methanol as solvent. Solutions of 2 mL were
applied to the HPTLC plates as spot bands of 6 mm using
LINOMAT V. Application positions were at least 15 mm
from the sides and 10 mm from the bottom of the plates.
Mobile phase components were mixed prior to use and the
development chamber was left for saturation with mobile
phase vapor for 10 min before each run. Development of the
plate was carried out by the ascending technique to a
migration distance of 7 cm. Then the plates were dried on a
hot plate. All the analyses were carried out in a laboratory
with temperature control (20–24 1C).
Densitometry scanning was done in absorbance mode at
276 nm using a deuterium lamp. The slit dimensions were set
at 6 mm 0.30 mm, the scanning speed of 10 mm/s, and the
data resolution at 100 mm/step. Single wavelength detection
was performed since the main components were only analyzed.
2.6. Method validation
The developed method was validated as per the International
Conference on Harmonization (ICH) [9,10] guidelines with
respect to linearity and range, speciﬁcity, precision, accuracy,
limit of detection and limit of quantiﬁcation.3. Results and discussion
3.1. Linearity and range
A stock standard solution was prepared for both Lamivudine
and Zidovudine; they were serially diluted to yield ﬁve
standard solutions. A volume of 2 mL of each solution was
applied to the HPTLC plate to deliver 50, 100, 150, 200 and
250 ng of Lamivudine per spot, 100, 200, 300, 400 and 500 ng
of Zidovudine per spot. This was done in triplicate and
repeated for three days. For each concentration, the applied
spot bands were evenly distributed across the plate to mini-
mize possible variation along the silica layer. The results are
indicated in Table 1.
3.2. Precision
The repeatability (intra-days precision) is expressed as percen-
tage relative standard deviations (% RSD) for the Lamivudine
at the concentrations of 50, 100 and 150 ng/spot, their %
RSD values were 0.48, 0.52 and 0.46, respectively, and for the
time-different intermediate precision (inter-days precision) the
% RSD values were 0.38, 0.62 and 0.39, respectively. The %
RSD values of intra-days precision for Zidovudine at the
concentrations of 100, 200 and 300 ng/spot were 0.34, 0.45,
0.68, and for inter-days precision the % RSD levels were 0.43,
0.82 and 0.52, respectively. The pooled repeatability precisions
Table 2 Accuracy and intermediate precision.
Drugs Concentration (ng/spot) Intra-day Inter-day
Accuracy (%)a Precision (% RSD) Accuracy (%)a Precision (% RSD)
Lamivudine 50 98.5771.27 0.48 98.8471.34 0.38
100 99.8371.24 0.52 99.7471.52 0.62
150 99.5871.32 0.46 99.2871.27 0.39
Zidovudine 100 99.2671.63 0.34 99.0571.12 0.43
200 98.6971.52 0.45 99.2171.36 0.82
300 99.3471.34 0.68 99.2871.27 0.52
aMean of three replicate.
Table 1 Linearity results.
Components Concentration range (ng/spot) Equation for regression line r2
Lamivudine 50–250 Y¼2319.86xþ22.69 0.9991
Zidovudine 100–500 Y¼3843.13xþ18.92 0.9995
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P. Venkatesh, M. Daggumati154were 0.49 and 0.56 for Lamivudine and Zidovudine concen-
trations, respectively, and the pooled time-different intermedi-
ate precisions were 0.50 and 0.59, respectively. The % RSD
levels of intra-day and inter-day precision were less than 1.0
in all cases, which indicated that there were no signiﬁcant
variations in the analysis of Lamivudine and Zidovudine at
the concentrations, which are shown in Table 2.-0.17 0.03 0.23 0.43 0.63 0.83 1.03
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Figure 2 Chromatogram of ﬁxed-dose tablet (Duovir, Cipla)
solution of Lamivudine and Zidovudine. Mobile phase—tolue-
ne:ethyl acetate:methanol (4:4:2, v/v/v), detection at 276 nm.3.3. Accuracy
The accuracy was assessed by the methodological recovery. The
recovery of the method was calculated by comparing the
determined concentration of spiked samples to the theoretical
concentrations. The mean percentage recovery for each compound
was calculated at each concentration level and reported with its
standard deviation. The intra-day and inter-day percentages of
accuracy obtained for Lamivudine at the concentrations of 50,
100, 150 ng/spot, and for Zidovudine at the concentrations of 100,
200 and 300 ng/spot, are respectively shown in Table 2. The %
recoveries of intra-day for Lamivudine were 98.5771.27%,
99.8371.24% and 99.5871.32%, respectively, the mean recovery
for all the concentration levels was 99.2671.72%.
For Zidovudine, the % recoveries of intra-day were 99.267
1.63%, 98.6971.52% and 99.3471.34%, respectively (Table 2).
The mean value covering all the concentration levels was
99.0971.46%.3.4. Limits of detection and quantiﬁcation
The limit of detection was found to be 2.23 ng/spot and
7.90 ng/spot for Lamivudine and Zidovudine, respectively.
The limit of quantiﬁcation was found to be 2.90 ng/spot and
8.85 ng/spot for Lamivudine and Zidovudine, respectively,
which was lower than that reported earlier [8,11].3.5. Speciﬁcity
The chromatogram of the solution, which was not spiked with
Lamivudine and Zidovudine, did not show any spot, while the
chromatogram of the solution of the tablet matrix spiked with
Lamivudine and Zidovudine showed clear, compact and well-
separated peaks of Lamivudine and Zidovudine (Fig. 2).
Moreover, from Fig. 2, it can be seen that no other peaks
were eluted besides the two active compounds. The method
was therefore considered to be speciﬁc.
There are two advantages in this method development over the
earlier reported methods. One is solvent system, a lower propor-
tion of ethyl acetate and methanol was used for the method
development of Lamivudine and Zidovudine instead of a higher
proportion of chloroform and methanol as reported in earlier
methods [8,11]. Second is lower limits of detection and
Simultaneous analysis of Lamivudine and Zidovudine in tablets by HPTLC method 155quantiﬁcation, they were 2.23 ng/spot and 7.90 ng/spot for
Lamivudine and 2.98 ng/spot and 8.85 ng/spot for Zidovudine,
which are lower than those reported earlier by Habte et al. [8] and
Sockalingam et al. [11]. By adjusting the relative proportion of
ethyl acetate and methanol reasonable retention time for Lami-
vudine and Zidovudine was obtained with good peak shape.
3.6. Results of analysis of tablets formulations
Analysis of samples of marketed antiretroviral tablets containing
Lamivudine 150 mg and Zidovudine 300 mg was carried out and
the amounts recovered were expressed as a percentage amount of
the label claims. The percentage recovery of Lamivudine and
Zidovudine was 99.2671.31 and 99.1471.14, respectively, and
these values are complying with the assay speciﬁcations for active
drugs in the United States of Pharmacopoeia (90.0–110.0%) [12],
which are required to be met by most drug formulations.4. Conclusion
A quick, precise and accurate method based on normal-phase
HPTLC has been developed for routine analysis of Lamivudine
and Zidovudine in ﬁxed-dose combination tablets. The method
was validated for linearity, precision, accuracy and speciﬁcity. It
has the advantage over HPLC methods in general. It consumed
less than 35 mL of mobile phase per run (8 samples per plate),
whereas HPLC methods would consume more than 50 mL per
runs of similar number of samples. If we consider the time from
sample preparation to densitometric evolution for one plate, the
new method took an average of 1 h, whereas HPLC methods
would generally take more than 2 h for the same number of
samples. It is cheap, quick and does not use chloroform,
therefore suitable for routine analysis of Lamivudine and
Zidovudine in ﬁxed-dose combination tablets. When compared
with the reported HPLC method, the developed HPTLC
method is both time and cost effective for the determination
of Lamivudine and Zidovudine mixtures.
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